A panel of leading academic and pharmaceutical investigators takes
stock of the remarkable work that has been accomplished to date
with proteasome inhibitors in cancer, and examines emerging
therapeutic possibilities. The topics range from a discussion of
the chemistry and cell biology of the proteasome and the rationale
for proteasome inhibitors in cancer to a review of current clinical
trials underway. The discussion of rationales for testing
proteasome inhibitors in cancer models covers the role of the
proteasome in NF-kB activation, the combining of conventional
chemotherapy and radiation with proteasome inhibition, notably
PS-341, new proteasome methods of inhibiting viral maturation, and
the role of protesome inhibition in the treatment of AIDS. The
authors also document the development of bortezomib (Velcade (TM))
in Phase I clinical trials and in a multicentered Phase II clinical
trials in patients with relapsed and refractory myeloma.
General
| Imprint: |
HumanaPress
|
| Country of origin: |
United States |
| Series: |
Cancer Drug Discovery and Development |
| Release date: |
November 2010 |
| First published: |
2004 |
| Editors: |
Julian Adams
|
| Dimensions: |
254 x 178 x 17mm (L x W x T) |
| Format: |
Paperback
|
| Pages: |
313 |
| Edition: |
Softcover reprint of hardcover 1st ed. 2004 |
| ISBN-13: |
978-1-61737-452-4 |
| Categories: |
Books >
Medicine >
Clinical & internal medicine >
Diseases & disorders >
Oncology >
General
|
| LSN: |
1-61737-452-0 |
| Barcode: |
9781617374524 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
